The original vaccine technology (papilloma pseudovirus) was co-developed by our chief executive officer Dr. Liang Qiao, an associate professor at Loyola University Chicago, and is owned by Loyola University Chicago. In June 2002, Loyola University exclusively licensed this technology to Bio-Bridge Science with respect to China (including mainland China, Taiwan, Hong Kong and Macau), Japan and the United States.


The technology involves a papilloma pseudovirus that can induce an immune response after oral intake. Human papilloma or bovine papilloma pseudovirus are made by disrupting their virus-like particles, mixing them with plasmids or DNA vaccine, and reassembling them into the pseudo-viruses (virus-like particles with plasmids inside). This pseudovirus does not cause any disease and thus can be applied in gene therapy or used as a vaccine or an adjuvant. The gene of interest can be inserted into a plasmid that is then packaged into virus-like particles which also can be modified to carry antigens of interest. Oral administration of the pseudovirus will deliver the genes or antigens to intestinal mucosal, systemic lymphoid tissues, and mucosal epithelium. The pseudovirus is different from other vaccines or gene-delivery vectors because most of them can only be injected subcutaneously or intramuscularly, but can’t be given orally. Most of the vaccines can induce only systemic immune responses, but not mucosal immune responses. Because many pathogens are transmitted through mucosa, this pseudovirus can induce effective immune responses to prevent and to treat mucosal infections caused by pathogens. These pathogens include bacteria such as salmonella and viruses such as HIV. Similarly, this pseudo-virus can be used to induce immune responses to treat tumors, in particular, mucosal tumors such as cervical cancer and colon cancer. This pseudovirus also induces much stronger immune responses than DNA vaccines in addition to its advantage as a delivery vector to mucosa.


Patent Numbers Of Our Core Technology:

• US patent number: US 6,878,541 B2

• China patent number: ZL 01 1 18003.x

• Japan application number: P2001-321828